Ruxolitinib-related treatment-emergent adverse events occurring in at least 5% of patients (safety-evaluable patients)
| Event . | Ruxolitinib (N = 71) . | |
|---|---|---|
| Any grade . | Grade 3/4 . | |
| Anemia | 25 (35.2) | 20 (28.2) |
| Platelet count decreased* | 23 (32.4) | 21 (29.6) |
| Neutrophil count decreased | 19 (26.8) | 15 (21.1) |
| White blood cell count decreased | 14 (19.7) | 8 (11.3) |
| Thrombocytopenia* | 11 (15.5) | 9 (12.7) |
| Alanine aminotransferase increased | 8 (11.3) | 1 (1.4) |
| Lymphocyte count decreased | 7 (9.9) | 7 (9.9) |
| Peripheral edema | 6 (8.5) | 1 (1.4) |
| Aspartate aminotransferase increased | 4 (5.6) | 0 |
| Dizziness | 4 (5.6) | 0 |
| Fatigue | 4 (5.6) | 1 (1.4) |
| Pneumatosis intestinalis | 4 (5.6) | 4 (5.6) |
| Pyrexia | 4 (5.6) | 1 (1.4) |
| Sepsis | 4 (5.6) | 4 (5.6) |
| Event . | Ruxolitinib (N = 71) . | |
|---|---|---|
| Any grade . | Grade 3/4 . | |
| Anemia | 25 (35.2) | 20 (28.2) |
| Platelet count decreased* | 23 (32.4) | 21 (29.6) |
| Neutrophil count decreased | 19 (26.8) | 15 (21.1) |
| White blood cell count decreased | 14 (19.7) | 8 (11.3) |
| Thrombocytopenia* | 11 (15.5) | 9 (12.7) |
| Alanine aminotransferase increased | 8 (11.3) | 1 (1.4) |
| Lymphocyte count decreased | 7 (9.9) | 7 (9.9) |
| Peripheral edema | 6 (8.5) | 1 (1.4) |
| Aspartate aminotransferase increased | 4 (5.6) | 0 |
| Dizziness | 4 (5.6) | 0 |
| Fatigue | 4 (5.6) | 1 (1.4) |
| Pneumatosis intestinalis | 4 (5.6) | 4 (5.6) |
| Pyrexia | 4 (5.6) | 1 (1.4) |
| Sepsis | 4 (5.6) | 4 (5.6) |
Data are presented as n (%). The data cutoff was 2 July 2018. Multiple occurrences of the same adverse event in 1 patient were counted only once per preferred term at the highest grade.
The terms “platelet count decreased” and “thrombocytopenia” were used by investigators when reporting adverse events, and therefore were recorded as separate terms in the safety database.